A Phase III Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma

Brief Summary

Type:
Lymphomas

Study Type:
Basic Science

Phase:
III

ClinicalTrials.gov Identifier:
NCT05371093

Study #:
STUDY00148937

Start Date:
Jan 20, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05371093

View Complete Trial Details & Eligibility at ClinicalTrials.gov